Analysts this morning are spotlighting varied stock trends, with Citi maintaining a cautious stance on Dr. Reddy’s ...

Hyderabad-based Dr Reddy’s Laboratories (DRL) recorded a 9.5 per cent decline in its consolidated profit after tax (PAT), ...

Indian pharmaceutical major, Dr Reddy’s Laboratories share surged 3.1 per cent at Rs 1,312 a piece on the BSE in Wednesday’s intraday deals. This came after the pharma major on Tuesday recorded its ...

The pharma major announced its Q2 earnings for the financial year 2024-25 on Tuesday. Shares of Dr Reddy's Laboratories ...

Dr. Reddy's' US sales continued to struggle due to inventory adjustments and pricing pressures on key products, Citi said.

Discover the Dr Reddys Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent ...

HYDERABAD/BENGALURU (Reuters) -Indian generic drugmaker Dr Reddy's Laboratories' second-quarter profit was hit by one-time charges related to its joint venture with Nestle India and Nicotinell ...

Despite reporting decent earnings for the July-September quarter, brokerages continue to maintain their neutral stance over ...

With Novo Nordisk’s patent on semaglutide set to expire in India, Dr Reddy’s is among the forerunners trying to bring the ...

Its consolidated profit after tax rose 17 per cent. Dr. Reddy’s Laboratories’ consolidated revenue was up 16.5 per cent to Rs ...

The Board of Directors of Dr. Reddys Laboratories Limited, at its meeting held today have approved the financial results of the company for the period ended September 30, 2024 - Q2 FY2024-25, H1 ...

The drugmaker’s total revenue from operations in the second quarter of current fiscal rose 16.5 per cent to ₹8,016 crore.